Replimune Group, Inc. (NASDAQ:REPL) Position Boosted by Nan Fung Group Holdings Ltd

Nan Fung Group Holdings Ltd boosted its position in Replimune Group, Inc. (NASDAQ:REPL) by 11.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 321,746 shares of the company’s stock after buying an additional 33,900 shares during the quarter. Replimune Group makes up about 3.3% of Nan Fung Group Holdings Ltd’s investment portfolio, making the stock its 12th biggest holding. Nan Fung Group Holdings Ltd owned approximately 0.47% of Replimune Group worth $3,896,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of REPL. Sterling Capital Management LLC grew its position in shares of Replimune Group by 364.5% during the 4th quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock valued at $26,000 after buying an additional 1,655 shares during the last quarter. Aster Capital Management DIFC Ltd boosted its stake in Replimune Group by 8,798.9% in the fourth quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company’s stock valued at $100,000 after acquiring an additional 8,183 shares during the period. XTX Topco Ltd bought a new position in shares of Replimune Group during the fourth quarter valued at approximately $137,000. Sei Investments Co. acquired a new stake in shares of Replimune Group during the 4th quarter worth approximately $148,000. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of Replimune Group in the 4th quarter worth approximately $150,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Stock Up 4.7 %

Shares of Replimune Group stock opened at $7.99 on Friday. Replimune Group, Inc. has a 12-month low of $4.92 and a 12-month high of $17.00. The firm has a market capitalization of $615.35 million, a PE ratio of -2.60 and a beta of 1.26. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14. The stock’s fifty day moving average is $10.75 and its 200-day moving average is $11.76.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Equities analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on REPL shares. HC Wainwright raised their target price on Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. lifted their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Finally, BMO Capital Markets upped their target price on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $19.43.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.